Bivalirudin Drug Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2028

  • Single User License $3500

Bivalirudin Drug Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2028

Status : November, 2021 | Pharmaceutical

Report Digest


Bivalirudin Drug Market Introduction

Bivalirudin is a synthetic residue peptide and it is direct thrombin inhibitor (DTI). It is an anticoagulant that helps to prevent the formation of blood clots, especially in people with severe chest pain or ones who are undergoing angioplasty. Bivalirudin is for IV use only and it is supplied as a sterile, lyophilized product, and glass vials. Moreover, Bivalirudin is also used conjuction with other medicines.

Bivalirudin drugs are finding wide application in patients undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA) and percutaneous coronary intervention (PCI) procedures. Bivalirudin is not given to patients with active major bleeding. The most common adverse health effects of Bivalirudin are pain, nausea, back pain, hypotension, and headache. Meanwhile, Bivalirudin is also approved for cardiac patients undergoing PCI. Bivalirudin is also partly cleared by renal mechanism, hence, the dose administration needs to be managed for patients with severe renal impairment.

Bivalirudin Drug Market: Notable Developments

  • Accord Healthcare has entered into the license agreement with Foresee Pharma. Under the agreement, Foresee will receive combination of regulatory, sales and upfront milestone, in addition to the significant share of the product revenue as Accord Healthcare will cover overall cost of commercialization in the global market with exception of Japan, mainland China, the US, and Taiwan, along with previously partnered territories including various countries in the Middle East, Turkey, and Israel.
  • Aurobindo Pharma has acquired Apotex’s commercial operations in five European countries including the Netherlands, Belgium, Poland, Spain, and the Czech Republic.
  • Beximo Pharmaceuticals Limited plans to buy eight ANDAs in the US from Sandoz Inc., a division of Novartis. Following this deal, Beximo Pharma will have 14 approved ANDAs in its product portfolio in the US.

Some of the most prominent competitors operating in the competitive landscape of global bivalirudin drug market include –

  • Sandoz
  • Dr. Reddys Laboratories
  • Fresenius Kabi
  • Apotex
  • The Medicines Company
  • Pfizer
  • Aurobindo Pharma
  • Mylan
  • Accord Healthcare
  • Sun Pharmaceuticals Industries Limited
  • Ferring Pharmaceuticals

Bivalirudin Drug Market Dynamics

Bivalirudin Drug as Alternative to Heparin for Anticoagulation in Children and Infants

Bivalirudin has emerged as an alternative for heparin for infants and children in anticoagulation. Moreover, Bivalirudin, unlike heparin, does not require antithrombin to be effective, thus providing more consistent anticoagulation. The use of DTI among children and infants has been uncommon. However, the primary reason for use of DTI is the development of thrombus or HIT extension during the heparin therapy.

Although the use of Bivalirudin is not common in pediatrics, the use of DTI is slowly increasing owing to the rise in diagnosis of HIT. Meanwhile, in various studies, researchers have found a significant reduction in the rate of bleeding after using DTI with Bivalirudin as compared to argatroban. Meanwhile, the first pilot study on use of Bivalirudin to treat thrombosis in infants was presented in 2007. After this more research has been done resulting in the successful use of Bivalirudin in various cases including children undergoing cardiac catheterization.

Increasing Use of Bivalirudin Drug in Patients Undergoing PCI

The acute coronary syndrome is emerging as the most common cause of death globally. This is driving the demand for Percutaneous Coronary Intervention (PCI) to manage acute coronary syndrome. In order to reduce the risk of thrombotic complications, the use of anticoagulation therapy is increasing during PCI, thereby, driving the demand for Bivalirudin drug as the anticoagulant drug as it reduces the risk of bleeding during the procedure. Moreover, Bivalirudin drug has also been licensed as an alternative to Heparin for the patients undergoing PCI and also for the patients with HIT who go for PCI.

The sale of Bivalirudin drug is also increasing as anticoagulant drug owing to the advantages as compared to similar drugs in the market. Moreover, Bivalirudin does not present complications including hemorrhagic and ischemic that are often caused by other anticoagulant drugs.

High Cost of Bivalirudin Drug to Restrain its Growth

Despite increasing use of Bivalirudin drug as a substitute for Heparin and other anticoagulant drugs, the high cost of Bivalirudin drug is restricting its use among patients with low or moderate risk of bleeding. Although, Bivalirudin has shown better results in patients undergoing PCI, its high cost may restrict its use among patients. Moreover, expenditure review by various healthcare institutions have also noted a significant increase in the contribution of Bivalirudin drug on the overall drug budget.

Various organizations and governments are focusing on cost saving initiatives to reduce the cost of Bivalirudin and also reduce its wastage by providing the dosage as required depending on the patient’s condition.

Bivalirudin Drug Market Segmentation

Based on the types, the Bivalirudin drug market is segmented into

  • Ready-to-use solution
  • Powder for reconstitution

On the basis of application, the Bivalirudin drug market is segmented into

  • Drug store
  • Hospital

By end use the Bivalirudin drug market is segmented into

  • Percutaneous Coronary Intervention (PCI) Procedures
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
  • Others

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach. The researchers compile the necessary information that enlightens the CXOs about the current growth opportunities in a specific market and enables them to make the most of the opportunities.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others. TMR Research reports help the stakeholders and CXOs make impactful decisions through a unique blend of innovation and analytical thinking. The use of innovation and analytical thinking while structuring a report assures complete and ideal information of the current status of the market to the stakeholders.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others.

5-Point Growth Formula

The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs.

The 5-point growth formula includes the following points:

  • Current and Future Threats
  • Accurate Trend Analysis
  • Regional Assessment
  • Industrial Analogy
  • COVID-19 Impact

Current and Future Threats

Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats.

Accurate Trend Analysis

Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues.

Regional Assessment

Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market.

Industrial Analogy

The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation.

COVID-19 Impact

The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly.

The reports offer answers to the top 7 questions that revolve around the growth of the market

  • What are the diverse growth parameters influencing the market?
  • Which regions will contribute largely to the growth of the market
  • What are the recent innovations and technological advancements in the market?
  • What are the emerging trends across the market?
  • How has COVID-19 affected the market?
  • What will be the post-pandemic scenario of the market?
  • What are the major threats that will dent the growth prospects of the market?